Rosner, Jan
de Andrade, Daniel C.
Davis, Karen D.
Gustin, Sylvia M.
Kramer, John L. K.
Seal, Rebecca P.
Finnerup, Nanna B. http://orcid.org/0000-0001-5541-0240
Article History
Accepted: 21 November 2023
First Online: 21 December 2023
Competing interests
: J.R. and J.L.K.K. receive consultancy fees from AXONIS Therapeutics. N.B.F. has received consultancy fees from Vertex, Novartis Pharma, NeuroPN, Nanobiotix, Neurvati and Samiona and has undertaken consultancy work for Aarhus University with remunerated work for Biogen, Merz and Confo Therapeutics. She has received grants from IMI2PainCare an EU IMI 2 (Innovative Medicines Initiative) public–private consortium and the companies involved include Grunenthal, Bayer, Eli Lilly, Esteve and Teva, outside the submitted work. The other authors declare no competing interests.